Managing Lung Cancer in the COVID-19 Era

The global COVID-19 pandemic has forced the medical community to reexamine every aspect of healthcare delivery. Patients with cancer, particularly lung cancer, are a vulnerable population and may be more prone to coronavirus infection or complications from infection. While our understanding of the relevant biology is still unfolding, immediate efforts to modify therapeutic strategies for patients with lung cancer are critical to mitigating patient risk. This can involve reducing visits to cancer centers, using alternate systemic agents felt to reduce risk, or altering the overall multidisciplinary approach. During times when peak infection may reduce available resources, innovative strategies will be born of necessity. This research topic explores potential approaches to managing patients with lung cancer in the COVID-19 era.

We are particularly interested in Mini Reviews, Reviews, Case Series covering the following topics:

-Use of oral cytotoxics
-Extended dosing intervals
-Hypofractionated radiation
-Palliative medicine
-SBRT over surgery
-Telemedicine
-Alternative treatment strategies for Lung Cancer
-Incidental lung cancer findings on COVID CTs
-Immunotherapy and COVID
-COVID pneumonitis vs ICI pneumonitis (radiologist)

***Due to the exceptional nature of the COVID-19 situation, Frontiers is waiving all article publishing charges for COVID-19 related research.***